e-learning
resources
Vienna 2012
Tuesday, 04.09.2012
Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Prevention and partial reversal of monocrotaline-induced pulmonary arterial hypertension (PAH) by hsp90 inhibitors
C. Dimitropoulou, C. Snead, S. Litwin, Y. Su, J. Catravas (Augusta, United States Of America)
Source:
Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Session:
Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Session type:
Thematic Poster Session
Number:
3910
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Dimitropoulou, C. Snead, S. Litwin, Y. Su, J. Catravas (Augusta, United States Of America). Prevention and partial reversal of monocrotaline-induced pulmonary arterial hypertension (PAH) by hsp90 inhibitors. Eur Respir J 2012; 40: Suppl. 56, 3910
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
The heat shock protein 90 inhibitor, 17-AAG, ameliorates pulmonary arteriolar and right ventricular hypertrophy in monocrotaline-induced pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary circulation II
Year: 2009
TRAM-34 ameliorates hypoxia-induced pulmonary arterial hypertension in rats
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Acute effect of sildenafil (PDE-5) on cardiopulmonary interactions in patients with pulmonary arterial hypertension (PAH) secondary to pulmonary fibrosis
Source: Annual Congress 2008 - Pulmonary hypertension II
Year: 2008
Current medical therapies in pulmonary arterial hypertension
Source: Eur Respir Mon 2012; 57: 26-41
Year: 2012
Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats
Source: Eur Respir J 2011; 37: 813-822
Year: 2011
Pregnancy and pulmonary arterial hypertension (PAH)
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II
Year: 2013
Effect of sitaxentan on haemodynamics and right ventricular hypertrophy in monocrotaline-induced pulmonary arterial hypertension (PAH)
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008
Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil
Source: Eur Respir J 2010; 36: 800-807
Year: 2010
Effect of riociguat on pulmonary arterial compliance (PAC) in patients with PAH in PATENT-1
Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights
Year: 2015
Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2017 – PAH and CTEPH
Year: 2017
Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients
Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Year: 2005
Effects of HIV protease inhibitors on monocrotaline-induced pulmonary hypertension in rats
Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases
Year: 2009
Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Human apyrase (APT102) treatment attenuates the development of severe pulmonary arterial hypertension (PAH)
Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments
Year: 2013
Effect of riociguat on pulmonary arterial compliance in patients with pulmonary arterial hypertension (PAH) in the RESPITE study
Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials
Year: 2017
Predictors of response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension
Source: Virtual Congress 2021 – Therapy of pulmonary hypertension
Year: 2021
HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Assessment of simvastatin treatment on pulmonary arterial hypertension
Source: Annual Congress 2008 - Pulmonary hypertension II
Year: 2008
Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition
Source: Eur Respir J 2013; 42: 869-870
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept